Navigation Links
Cardium Reports on Transdel Transaction
Date:7/28/2011

cialization, partnering and other economic monetizations.  Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio.  News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations.  For example, there can be no assurance that the proposed Transdel transaction or any other transactions under consideration will be completed; that our stockholder's equity can be increased and maintained to a sufficient level to satisfy ongoing compliance with the requirements of our listing stock exchange; that Ketotransdel can be successfully developed to result in an FDA Section 505(b)(2) registered product in the United States; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, or that clinical studies even if successful will lead to product advancement or partnering; that the U.S. Food and Drug Administration (the "FDA") will grant marketing clearance of Ketotransdel or other product candidates or that we or a partner can successfully introduce these or additional products into topical NSAID markets in the U.S. or elsewhere; that Ketotransdel or other product candidates will prove to be sufficiently safe
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cardium Announces Market Introduction of New Alena™ Clinical Strength Carb Blocker to Expand the MedPodium Healthy Lifestyle Product Line
2. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
3. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
4. Cardium Presents First Quarter 2011 Financial Results and Reports on Near-Term Milestones
5. Cardium to Present at OneMedForum San Francisco 2011 Conference
6. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
7. Cardium Reports on Fourth Quarter and Year-End 2009 Financial Results and Recent Developments
8. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
9. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
10. Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
11. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... RIVER EDGE, N.J. , May 23, 2013 /PRNewswire/ ... ), a commercial stage medical device company that develops ... the successful completion of its rights offering.  In addition, ... company,s March 2011 warrants expired on May 17, 2013. ... proceeds of $3.0 million from the rights offering.   A ...
(Date:5/23/2013)... , May 23, 2013  A recently published ... Houston, Texas , demonstrates that 3D ... increasing cancer detection. The study, "Implementation ... Observational Study," was led by Stephen L. ... issue of the American Journal of Roentgenology ...
(Date:5/23/2013)... IRVINE, Calif. , May 23, 2013 ... breast cancer may not benefit from chemotherapy and still ... announced the launch of one of the largest sources ... The new website and interactive Facebook page provide recently ... if they can safely avoid chemotherapy. "We ...
Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3
... CeloNova BioSciences, Inc.,("CeloNova"), leading and accelerating ... innovative medical devices, has released data,from THE ... study of uterine fibroid,embolization using the Company,s ... the 20th Annual International Symposium on,Endovascular Therapy., ...
... Disease Indication for HUMIRA Provides Patients with Visible, ... Chronic Autoimmune Disease, ABBOTT PARK, Ill., Jan. ... it has received U.S. Food and Drug Administration ... for adult patients,with moderate to severe chronic plaque ...
Cached Medicine Technology:CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids 2Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 2Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 3Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 4Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 5Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 6Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 7
(Date:5/23/2013)... , , THURSDAY, May 23 (HealthDay News) -- Glucosamine supplements ... and knee osteoarthritis may have an unexpected side effect: ... new study of older adults suggests. Glaucoma ... (IOP) or pressure inside the eye. Left untreated, glaucoma ... In the new study of 17 people, ...
(Date:5/23/2013)... -- A modified version of the polio virus ... research suggests. Scientists at Duke Cancer Institute ... uses an engineered form of the virus that ... cells. The therapy shows promise in the treatment ... tumor, they said. "These early results are ...
(Date:5/23/2013)... (HealthDay News) -- People who eat at fast-food restaurants ... and teens are the worst offenders, a new study ... their meals by as much as 34 percent, parents ... and adults by as much as 20 percent," study ... release from the Robert Wood Johnson Foundation, which helped ...
(Date:5/23/2013)... Memorial Day Focus Spotlight on Military ... a part of the U.S. Military for more than ... it, these men and women will be honored for ... America. As veterans transition to civilian life, there ... workplace chaplaincy world. , Marketplace Chaplains, America’s original ...
(Date:5/23/2013)... (May 23, 2013)Don,t doubt it when a woman harried ... remembering things. A new study published online in ... Society (NAMS), helps confirm with objective tests that what ... In the past, some studies showed that hot flashes ... studies showed that, even though there was a relationship ...
Breaking Medicine News(10 mins):Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2Health News:How Many Calories in Your Fast-Food Meal? Guess Again 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3
... May 26, 2010 Complete Genomics Inc., a third-generation ... a wholly owned member of the Roche Group (SIX: ... and analytics services to sequence and compare a patient,s ... like this allow researchers to compare the patient,s genome ...
... amounts in the gums, those tough pink tissues that hold the ... to develop an early, non-invasive test for gum disease, the No. ... quart of which people produce each day, but gingival crevicular fluid ... tooth. The study, the most comprehensive analysis of GCF to date, ...
... People undergoing bisphosphonate therapy to prevent or treat osteoporosis (a ... and possible adverse side effects on oral health, according to ... of the American Dental Association (JADA). , Use of ... bisphosphonate-associated osteonecrosis of the jaw (BON) that occurs spontaneously or ...
... ... at over 3,000 retail sites. , ... (PRWEB) May 26, 2010 -- Buckts Firefox Add-on delivers discounts and ... purchase. When a shopper visits an online retailer, clicking on the highlighted ShoppingBuckt ...
... ... $100,000 per-violation penalties , ... Alexandria, VA (Vocus) May 26, 2010 -- More than ten major retailers, representing ... offered by the National Association of Chain Drug Stores (NACDS) and RollStream. ...
... expected changes to oversight of supplement industry , WEDNESDAY, ... dietary herbal supplements has found trace amounts of lead, ... tested, plus myriad illegal health claims made by supplement ... , The levels of heavy metal contaminants did not ...
Cached Medicine News:Health News:Genentech uses Complete Genomics' human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature 2Health News:Some bisphosphonates users unfamiliar with drug's possible side effects on oral health 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 3Health News:Many Supplements Said to Contain Toxins, Make False Health Claims 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: